Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer

NCT00268346 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: ZD1839

Sponsor

Case Comprehensive Cancer Center

Collaborators

[object Object]